Publications found:
61,963
Sort by:
Cholera R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cholera Pipeline Overview The Q4 Cholera pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Cholera...
October 2020
51 pages
Coccidioidomycosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Coccidioidomycosis Pipeline Overview The Q4 Coccidioidomycosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
51 pages
Cryptococcosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cryptococcosis Pipeline Overview The Q4 Cryptococcosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
62 pages
Cryptosporidiosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cryptosporidiosis Pipeline Overview The Q4 Cryptosporidiosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under dev...
October 2020
35 pages
Dengue Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Dengue Fever Pipeline Overview The Q4 Dengue Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
163 pages
Diabetic Neuropathy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Diabetic Neuropathy Pipeline Overview The Q4 Diabetic Neuropathy pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
142 pages
Diphtheria R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Diphtheria Pipeline Overview The Q4 Diphtheria pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for D...
October 2020
92 pages
Genital Herpes R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Genital Herpes Pipeline Overview The Q4 Genital Herpes pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
128 pages
Gonorrhea R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Gonorrhea Pipeline Overview The Q4 Gonorrhea pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Gon...
October 2020
94 pages
Grass Pollen Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Grass Pollen Allergy Pipeline Overview The Q4 Grass Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
62 pages
Hepatitis A R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hepatitis A Pipeline Overview The Q4 Hepatitis A pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
57 pages
Hepatitis C (HCV) R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Hepatitis C (HCV) Pipeline Overview The Q4 Hepatitis C (HCV) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under dev...
October 2020
210 pages
Hepatitis D R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hepatitis D Pipeline Overview The Q4 Hepatitis D pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
62 pages
Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hereditary Angioedema Pipeline Overview The Q4 Hereditary Angioedema pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under...
October 2020
104 pages
Hyperglycemia R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hyperglycemia Pipeline Overview The Q4 Hyperglycemia pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under develop...
October 2020
30 pages
Hyperinsulinemia R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hyperinsulinemia Pipeline Overview The Q4 Hyperinsulinemia pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
63 pages
Hypoglycemia R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hypoglycemia Pipeline Overview The Q4 Hypoglycemia pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
81 pages
Impetigo R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Impetigo Pipeline Overview The Q4 Impetigo pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Impet...
October 2020
51 pages
Influenza B Infections R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Influenza B Infections Pipeline Overview The Q4 Influenza B Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs...
October 2020
162 pages
Insulin Resistance R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Insulin Resistance Pipeline Overview The Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs und...
October 2020
53 pages
Japanese Encephalitis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Japanese Encephalitis Pipeline Overview The Q4 Japanese Encephalitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
51 pages
Kaposi Sarcoma R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Kaposi Sarcoma Pipeline Overview The Q4 Kaposi Sarcoma pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
72 pages
Lassa Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Lassa Fever Pipeline Overview The Q4 Lassa Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
65 pages
Lyme Disease R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Lyme Disease Pipeline Overview The Q4 Lyme Disease pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
68 pages
